Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00810485 | ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) | PHASE2 | COMPLETED | 298 | — | — | Dec 1, 2008 | - | Jul 16, 2012 | 40 | United States, France +3 |
| NCT00820079 | ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) | PHASE2 | COMPLETED | 120 | — | — | Dec 1, 2008 | - | Dec 24, 2009 | 11 | Austria, Belgium +2 |
| Arm | Type | Description |
|---|---|---|
| ADX10059 50 mg | EXPERIMENTAL | twice-daily |
| ADX10059 100 mg | EXPERIMENTAL | twice-daily |
| ADX10059 150 mg | EXPERIMENTAL | twice-daily |
| ADX10059 Matching Placebo | PLACEBO_COMPARATOR | twice-daily |
| ADX10059 120 mg | EXPERIMENTAL | Twice-daily |
| Name | Type | Description |
|---|---|---|
| ADX10059 | DRUG | oral administration |
| ADX10059 Matching Placebo | DRUG | oral administration |
Inclusion Criteria: * diagnosis of typical GERD * partial responder to a stable standard clinical symptoms control dose of PPI therapy * body mass index ≤ 32 kg/m2 Exclusion Criteria: * exclusively atypical symptoms of GERD * symptoms that have been shown not to be associated with GERD * erosive ...